The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis

OBJECTIVES: Adding bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF), to platinum-based chemotherapy/pemetrexed in 1(st) line treatment of advanced malignant pleural mesothelioma (MPM), significantly improved overall survival. However, increased high grade bleeding after operation was r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauk, Olivia, Bruestle, Karina, Neuer, Thomas, Battilana, Bianca, Nguyen, Thi Dan Linh, Frauenfelder, Thomas, Stahel, Rolf, Weder, Walter, Curioni-Fontecedro, Alessandra, Opitz, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693632/
https://www.ncbi.nlm.nih.gov/pubmed/33304848
http://dx.doi.org/10.3389/fonc.2020.588563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693632/
https://www.ncbi.nlm.nih.gov/pubmed/33304848
http://dx.doi.org/10.3389/fonc.2020.588563

Ejemplares similares